默沙东与DR. Falk Pharma Gmbh签署协议,获得Mk-8690(PRA-052)这一实验性抗Cd30配体单克隆抗体的部分研发和商业化权利。
默沙东与DR. Falk Pharma Gmbh签署协议,获得Mk-8690(PRA-052)这一实验性抗Cd30配体单克隆抗体的部分研发和商业化权利。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.